These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32285564)

  • 1. Brodalumab: A new way to inhibit IL-17 in psoriasis.
    Facheris P; Valenti M; Pavia G; Guanziroli E; Narcisi A; Borroni RG; Costanzo A
    Dermatol Ther; 2020 May; 33(3):e13403. PubMed ID: 32285564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.
    Vidal S; Puig L; Carrascosa-Carrillo JM; González-Cantero Á; Ruiz-Carrascosa JC; Velasco-Pastor AM
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brodalumab for the treatment of psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL17 therapies for psoriasis.
    Silfvast-Kaiser A; Paek SY; Menter A
    Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.
    Johansen C; Usher PA; Kjellerup RB; Lundsgaard D; Iversen L; Kragballe K
    Br J Dermatol; 2009 Feb; 160(2):319-24. PubMed ID: 19016708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
    Kivelevitch DN; Menter A
    Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis.
    Villalpando-Vargas FV; Rivera-Valdés JJ; Alvarado-Navarro A; Huerta-Olvera SG; Macías-Barragán J; Martínez-López E; Graciano-Machuca O
    Inflamm Res; 2021 Dec; 70(10-12):1201-1210. PubMed ID: 34705056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
    Timmermann S; Hall A
    Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.
    Tollenaere MAX; Hebsgaard J; Ewald DA; Lovato P; Garcet S; Li X; Pilger SD; Tiirikainen ML; Bertelsen M; Krueger JG; Norsgaard H
    Br J Dermatol; 2021 Sep; 185(3):585-594. PubMed ID: 33792895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
    Tong Y; Peranteau AJ; Nawas Z; Tyring SK
    Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of IL-17 in psoriasis.
    Malakouti M; Brown GE; Wang E; Koo J; Levin EC
    J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-17 treatment of psoriasis.
    Jinna S; Strober B
    J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
    Roman M; Chiu MW
    Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
    Plachouri KM; Chourdakis V; Georgiou S
    Drugs Today (Barc); 2019 Sep; 55(9):587-593. PubMed ID: 31584575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
    Russell CB; Rand H; Bigler J; Kerkof K; Timour M; Bautista E; Krueger JG; Salinger DH; Welcher AA; Martin DA
    J Immunol; 2014 Apr; 192(8):3828-36. PubMed ID: 24646743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.